NCT05688046View on ClinicalTrials.gov

Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients

CompletedOBSERVATIONAL
Enrollment

79

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

August 1, 2022

Study Completion Date

December 31, 2022

Conditions
NSCLC
Interventions
DRUG

Immune checkpoint inhibitors plus angiogenesis inhibitors

PD-(L)1-based therapy plus Bevacizumab or Anlotinib

DRUG

Immune checkpoint inhibitors without angiogenesis inhibitors

PD-(L)1-based therapy

Trial Locations (1)

215001

The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou

All Listed Sponsors
lead

Suzhou Municipal Hospital

OTHER

NCT05688046 - Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients | Biotech Hunter | Biotech Hunter